

# Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP

NCT04985318

---

**Status** RECRUITING  
**Sponsor** University of Cologne  
**Enrollment** 350 participants

## Key Eligibility Criteria

---

### Inclusion (4)

- Confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenic purpura
- Treatment with at least one single dose of caplacizumab (10 mg i.v. or s.c.)
- Male or female patients e 18 years of age
- signed written informed consent

### Exclusion (2)

- Hereditary thrombotic thrombocytopenic purpura
- disability to give informed consent

## Locations (1 total)

---

University Hospital of Cologne, Cologne, Germany